Key Highlights
- Acurx Pharmaceuticals shares finished the session up 18% at $1.65.
- The FDA granted conditional acceptance of CIFBEZY as the proprietary name for ibezapolstat.
- The name acceptance was complemented by a Trademark allowance from the USPTO.
- The company is advancing its lead CDI antibiotic into a global Phase 3 registration program.
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) shares finished the session up 18% at $1.65 after the company confirmed that the FDA granted conditional acceptance of CIFBEZY as the proprietary name for ibezapolstat.
What Happened
The name acceptance was complemented by a trademark allowance from the USPTO, milestones that enhance commercial preparation as the company advances its lead CDI antibiotic into a global Phase 3 registration program targeting infection resolution and recurrence prevention.
Market Reaction
Shares rose as investors responded to the commercial preparation milestones, viewing the conditional Brand name acceptance and trademark allowance as steps that support ibezapolstat's path toward eventual commercialization.
Outlook
Continued progress on the global Phase 3 registration program for ibezapolstat, targeting infection resolution and recurrence prevention in CDI, represents the next major disclosed milestone for Acurx Pharmaceuticals.
FAQs
Q: Why did Acurx Pharmaceuticals shares rise 18%?
A: Shares rose after the FDA granted conditional acceptance of CIFBEZY as the proprietary name for ibezapolstat, complemented by a USPTO trademark allowance.
Q: What is ibezapolstat being developed to treat?
A: Clostridioides difficile infection (CDI), as the company's lead antibiotic candidate.
Q: What is the next step for ibezapolstat?
A: A global Phase 3 registration program targeting infection resolution and recurrence prevention.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.